In recognition of this vulnerability, combination with a FASN inhibitor and trastuzumab sensitized trastuzumab-resistant breast cancer cell lines by downregulating HER2 expression (Vazquez-Martin et al., 2007a). Here, ERBB2 is linked to breast carcinoma.